Assessment of pain in patients with rheumatic disease under biological therapy treatment
DOI:
https://doi.org/10.23938/ASSN.1020Keywords:
Rheumatic diseases, Pain, Biological therapies, AnalgesicsAbstract
Background. To assess pain in patients with rheumatic disease under biological therapy treatment.
Methods. Observational retrospective study of patients with rheumatic disease under biological therapy treatment who visited the health care center as outpatients in February/August 2020. We collected demographic (sex and age), clinical (diagnosis, pain presence, intensity, and location), and pharmacological (biological therapy, concomitant treatment with traditional DMARDs, and analgesic treatment) variables from the electronic medical records and Farmatools Dominion®.
Results. We included 138 patients; mean age was 56 years and 71% were female. The most frequent diagnosis (47%) was ankylosing spondylitis. Anti-TNF-α was the most prescribed biological drug (64%); 60.1% of study patients received traditional drugs, particularly methotrexate and leflunomide (51.8 and 28.9%, respectively). Pain was reported in 81% of the cases, particularly in hands (73.2%) and knees (69.6%); mean pain intensity was 6.5 (VAS). Although 83.3% of the patients had been prescribed analgesics, pain persisted in 84.8% of the cases (VAS >4), being severe or very severe in 67.9%. Over half of the patients (52.2%) used more than one analgesic. The most frequently prescribed medications were non-steroidal anti-inflammatory drugs (NSAIDs) (60%), paracetamol (52.2%), and opioids (56.5%). NSAIDs controlled pain (14.5%) better than opioids (8.3%); there was no post-treatment improvement of pain in 29.6% of the patients. The number of prescribed drugs increased with pain intensity (rho = 0.264; p = 0.006).
Conclusion.: Almost 70% of study patients had uncontrolled severe rheumatic-related pain. This implies a challenge for establishing effective treatments for this type of pain.
Downloads
References
PUNTILLO KA, WHITE C, BONHAM MORRIS A et al. Patients perceptions and responses to procedural pain: results from Thunder Project II. American Journal of Critical Care 2001; 10: 238–251.
CLARETT M, PAVLOTSKY V. Escalas de evaluación de dolor y protocolo de analgesia en terapia intensiva. [Internet Monografías] 2012.
LYNCH ME, CRAIG KD, PENG PWH. Clinical pain management: a practical guide. Oxford: Wiley-Blackwell 2011.
BELLAMY N, BRADLEY LA. Workshop on chronic pain, pain control, and patient outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1996; 39: 357-362. https://doi.org/10.1002/art.1780390302
FITZCHARLES MA, SHIR Y. Management of chronic pain in the rheumatic diseases with insights for the clinician. Ther Adv Musculoskel Dis. 2011; 3: 179-190. https://doi.org/10.1177/1759720X11408999
AZEVEDO LF, COSTA-PEREIRA A, MENDONÇA L, DIAS CC, CASTRO-LOPES JM. Epidemiology of chronic pain: a population-based nationwide study on its prevalence, characteristics and associated disability in Portugal. J Pain 2012; 13: 773-783. https://doi.org/10.1016/j.jpain.2012.05.012
KALSO E, ALLAN L, DELLEMJIN P, FAURA CC, ILIAS WK, JENSEN TS et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003; 7: 381-386. https://doi.org/10.1016/S1090-3801(02)00143-X
DIEPPE P. Chronic Musculoskeletal Pain. BMJ 2013; 346: f3146. https://doi.org/10.1136/bmj.f3146
The Pain Society. Recommendations for the appropriate use of opioids for persistent non-cancer pain. London: The Pain Society 2004. https://www.palliativedrugs.com/download/opioids_doc_2004.pdf
JOVEY RD, ENNIS J, GARDNER-NIX J, GOLDMAN B, HAYS H, LYNCH M et al. Use of opioid analgesics for the treatment of chronic noncancer pain- a consensus statement and guidelines from The Canadian Pain Society 2002. Pain Res Manag 2003; 8 (Suppl A): A3-28. https://doi.org/10.1155/2003/436716
BREIVIK H, COLLETT B, VENTAFRIDDA V, COHEN R, GALLACHER D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287–333. https://doi.org/10.1016/j.ejpain.2005.06.009
Instituto Nacional de Estadística. Encuesta Nacional de Salud 2018. Problemas o enfermedades crónicas o de larga evolución padecidas en los últimos 12 meses y diagnosticadas por un médico en población adulta según sexo y grupo de edad. Población de 15 y más años. http://www.ine.es/jaxi/Tabla.htm?path=/t15/p419/a2011/p04/l0/&file=04027.px&L=0 []
TORNERO MOLINA J, ATANCE MARTINEZ JC, GRUPELI BE, VIDAL FUENTES J. Economic and social impact of rheumatic short-term work disability in Guadalajara. Rev Esp Reumatol 1998; 25: 340-345.
LOZA E, JOVER JA, RODRIGUEZ-RODRIGUEZ L, CARMONA L. Observed and expected frequency of comorbid chronic diseases in rheumatic patients. Ann Rheum Dis 2008; 67: 418-421. https://doi.org/10.1136/ard.2007.078659
FERNANDEZ-LOPEZ JC, LAFFON A, BLANCO FJ, CARMONA L. Prevalence, risk factors, and impact of knee pain suggesting osteoarthritis in Spain. Clin Exp Rheumatol 2008; 26: 324-332.
CASALS M, SAMPER D. Epidemiología, prevalencia y calidad de vida del dolor
crónico no oncológico. Estudio ITACA. Rev Soc Esp Dolor 2004; 11: 260-269.
BADLEY EM. The provision of reumatological services. En: Klippel JH, Dieppe PA, editores. Rheumatology. London: Mosby UK; 1995.
BATLLE-GUALDA E, CARMONA L, GAVRILA D, GARCIA CRIADO EI, RUIZ MIRAVALLES R, CARBONELL ABELLO J. ArtRoCad: health resources utilization and socioeconomic impact of knee and hip osteoarthritis. I. Methods and population characteristics. Reumatol Clin 2006; 2: 224-234. https://doi.org/10.1016/S1699-258X(06)73052-2
GAMERO RUIZ F, GABRIEL SANCHEZ R, CARBONELL ABELLO J, TORNERO MOLINA J, SANCHEZ-MAGRO I. Pain in Spanish rheumatology outpatient offices: EPIDOR epidemiological study. Rev Clin Esp 2005; 205: 157-163. https://doi.org/10.1157/13074161
PLANA VERET C, SEOANE MATO D, GOBBO MONTOYA M, VIDAL FUENTES J, Grupo de Trabajo del Proyecto EVADOR. Evaluación del dolor en Reumatología. Estudio EVADOR. Reumatol Clin 2021; 17: 88-96. https://doi.org/10.1016/j.reuma.2019.01.006
UGARTE-GIL MF, ACEVEDO-VÁSQUEZ EM, S. ALARCÓN G. Terapia biológica en enfermedades reumatológicas. Rev Med Hered 2013; 24: 141-155. https://doi.org/10.20453/rmh.v24i2.597
TORNERO MOLINA J, SANMARTI SALA R, RODRIGUEZ VALVERDE V, MARTIN MOLA E, MARENCO DE LA FUENTE JL, GONZÁLEZ ÁLVARO I et al. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin 2010; 6: 23–36. https://doi.org/10.1016/j.reuma.2009.10.006
CARMONA L, BALLINA J, GABRIEL R. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 2001; 60: 1040-1045. https://doi.org/10.1136/ard.60.11.1040
TORNERO-MOLINA J, VIDAL-FUENTES J, ALONSO-RUIZ A, ACEBES-CACHAFEIRO C, ARBOLEYA-RODRÍGUEZ L, CALVO-ALEN J et al. Documento de consenso de la Sociedad Española de Reumatología para el uso de opioides en el tratamiento del dolor reumático. Reumatol Clin 2006; 2 (Suppl 1): S50-S54. https://doi.org/10.1016/S1699-258X(06)73083-2
ATXOTEGI SAENZ DE BURUAGA J. Validez de la escalera analgésica de la OMS en Reumatología. Semin Fund Esp Reumatol 2006; 7: 121-127. https://doi.org/10.1016/S1577-3566(06)75090-4
ZELMAN DC, HOFFMAN DL, SEIFELDIN R, DUKES EM. Development of a metric for a day of manageable pain control: derivation of pain severity cut-points for low back pain and osteoarthritis. Pain 2003; 106: 35-42. https://doi.org/10.1016/S0304-3959(03)00274-4
SAMPER BERNAL D, ALVARADO BONILLA A, CÁNOVAS L, CARREGAL A, FERNÁNDEZ SÁNCHEZ SP, GONZÁLEZ MESA et al. Documento de consenso sobre el uso de la combinación paracetamol/tramadol en pacientes con dolor moderado-intenso. Semergen 2019; 45: 52-62. https://doi.org/10.1016/j.semerg.2018.08.004
ALCÁNTARA MONTERO A, BALSALOBRE GÓNGORA S, NARGANES PINEDA DM, BLANCO POLANCO B. Analgesia multimodal y sinergia farmacológica en el manejo del dolor. Semergen 2020; 46: 284-285. https://doi.org/10.1016/j.semerg.2020.01.005
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
